

EOS Imaging enter into agreement with Fosun Pharma

19 July 2018 | News

At the closing of the investment, the Company will issue 3,446,649 new shares to be subscribed by Fosun Pharmaceutical AG at a nominal value of €0.01.



EOS imaging, the pioneer of orthopedic medical imaging 2D / 3D, has entered into a binding agreement with Fosun Pharmaceutical AG, an indirect subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., related to an equity investment to be made by Fosun Pharmaceutical AG through an issuance of EOS imaging new shares.

At the closing of the investment, the Company will issue 3,446,649 new shares to be subscribed by Fosun Pharmaceutical AG at a nominal value of €0.01, for a price per share of €4.37, issue premium included, which amounts to a total amount of c. €15.1million.

Fosun Pharma, through Fosun Pharmaceutical AG, will hold approximately 13.2% of the sum of the Company's existing Shares and the shares subscribed by Fosun Pharma post transaction and will be the largest shareholder of the Company.

Following the resignation of Paula Ness Spears from her Board position, Antoine Vidal representing Fosun Pharmaceutical AG will be appointed at the closing of the investment as Board member by co-optation of the Board of Directors of the Company.